ANXA2 and breast cancer: The in vitro testing of AnxA2-Cur-PLGA-NPs against the BC cells (MDA-MB-231) showed a significant increase in the cell uptake efficiency, reduction in cell proliferation, migration, and invasion, metastasis, and growth [136].